Abstract
Hairy cell leukemia represent 2% of all the leukemias. The etiology is unknown. The diagnosis is based on the peripheral blood examination, showing characteristic lymphoid B cells, with loose lacy chromatin and unconstant cytoplasmic projections. The abnormal lymphoid cells express CD19, CD20, CD22, CD79a, CD25 and CD103. The tumor cells are Sig + with clonal light chain restriction. The treatment is based on recombinant IFN: we discuss the interest and the risks of second malignancy related to the prescription of the purine analogues.
MeSH terms
-
2-Chloroadenosine / adverse effects
-
2-Chloroadenosine / analogs & derivatives
-
2-Chloroadenosine / therapeutic use
-
Antigens, CD / analysis
-
Antimetabolites, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
B-Lymphocytes / pathology
-
Bone Marrow / pathology
-
Clinical Trials as Topic
-
Deoxyadenosines / adverse effects
-
Deoxyadenosines / therapeutic use
-
Humans
-
Immunologic Factors / adverse effects
-
Immunologic Factors / therapeutic use
-
Interferon Type I / adverse effects
-
Interferon Type I / therapeutic use
-
Leukemia, Hairy Cell* / drug therapy
-
Leukemia, Hairy Cell* / pathology
-
Leukemia, Hairy Cell* / therapy
-
Neoplasm Proteins / analysis
-
Neoplasms, Second Primary / chemically induced
-
Neoplastic Stem Cells / pathology
-
Pentostatin / adverse effects
-
Pentostatin / therapeutic use
-
Receptors, Antigen, T-Cell, gamma-delta / analysis
-
Recombinant Proteins
-
Splenectomy
-
Vidarabine / adverse effects
-
Vidarabine / analogs & derivatives
-
Vidarabine / therapeutic use
Substances
-
Antigens, CD
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Deoxyadenosines
-
Immunologic Factors
-
Interferon Type I
-
Neoplasm Proteins
-
Receptors, Antigen, T-Cell, gamma-delta
-
Recombinant Proteins
-
2-Chloroadenosine
-
Pentostatin
-
Vidarabine
-
2-chloro-3'-deoxyadenosine
-
fludarabine